Veracyte's Truemrd Bladder Cancer Test Secures Medicare Coverage, Boosting Commercial Outlook
VCYT sits 68% above its 52-week low of $22.61.
Summary
Veracyte has secured crucial Medicare coverage for its Truemrd monitoring test, designed for muscle-invasive bladder cancer, with availability starting June 1, 2026. This development is highly significant as Medicare coverage is essential for the commercialization and broad adoption of diagnostic tests in the United States, directly enabling reimbursement for patients and healthcare providers. The news substantially expands the addressable market and revenue potential for Veracyte's Truemrd platform. This positive product milestone follows the company's strong first-quarter 2026 financial results reported earlier this month. Investors will now watch for updates on the test's commercial rollout and its impact on future revenue growth.
At the time of this announcement, VCYT was trading at $38.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $22.61 to $50.71. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.